SHIAN-YING SUNG2026-10-162026-10-162019-01-01Pure ID: 15446660Pure UUID: e8582e0d-5ffb-4b42-9f50-f28b27f1175010.1007/978-1-4939-8922-5_3https://www.scopus.com/pages/publications/85058589961https://scholars.csmu.edu.tw/handle/123456789/28013Suicide gene therapy using the herpes simplex virus thymidine kinase (HSV-tk) gene, combined with the prodrug ganciclovir (GCV) medication, is a promising approach for the treatment of malignant tumors, including prostate cancer. The success of this therapeutic strategy requires tissue- or tumor-specific gene expression and efficient gene delivery. In this chapter, we describe the experimental protocols of key methodologies, including promoter construction, reporter assay, adenoviral vector construction and preparation, HSV-tk enzymatic assay and cytotoxicity assay to evaluate the specificity and efficacy of osteonectin promoter-mediated HSV-tk/GCV suicide gene therapy of prostate cancer.16enjournal article